1
Enzo Paoletti, Marion E Perkus, Jill Taylor, James Tartaglia, Elizabeth K Norton, Michel Riviere, Charles de Taisne, Keith J Limbach, Gerard P Johnson, Steven E Pincus, William I Cox, Jean Christophe F Audonnet, Russell R Gettig: NYVAC vaccinia virus recombinants comprising heterologous inserts. Virogenetics Corporation, Curtis Morris & Safford, February 27, 1996: US05494807 (99 worldwide citation)

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the ...


2
Enzo Paoletti, Marion E Perkus: Genetically engineered vaccine strain. Virogenetics Corporation, Curtis Morris & Safford, November 15, 1994: US05364773 (63 worldwide citation)

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the ...


3
Han Soo Joo: Low pathogencity PRRS live virus vaccines and methods of preparation thereof. Regents of the University of Minnesota, Hovey Williams Timmons & Collins, November 25, 1997: US05690940 (62 worldwide citation)

Live or modified live PRRS vaccines for administration to swine are provided which are of low virulence and confer effective immunity against PRRS. The preferred vaccines include virus isolates having average plaque diameters of less than about 2 mm and low pathogenicity. A preferred vaccine include ...


4
Peter R Paradiso, Stephen W Hildreth, Branda T Hu, Antonia Martin Gallardo, Rasappa Arumugham: Respiratory syncytial virus: vaccines. Praxis Biologics, Alan M Gordon, Geraldine F Baldwin, June 29, 1993: US05223254 (59 worldwide citation)

Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion ...


5
Enzo Paoletti, Marion E Perkus, Jill Taylor, James Tartaglia, Elizabeth K Norton, Michel Riviere, Charles de Taisne, Keith J Limbach, Gerard P Johnson, Steven E Pincus, William I Cox, Jean Christophe Francis Audonnet, Russell Robert Gettig: Alvac canarypox virus recombinants comprising heterlogous inserts. Virogenetics Corporation, William S Frommer, Thomas J Kowalski, Frommer Lawrence & Haug, May 26, 1998: US05756103 (51 worldwide citation)

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the ...


6
Cheng Xiong, Robert B Grieve: Recombinant packaging defective Sindbis virus vaccines. Heska Corporation, June 16, 1998: US05766602 (43 worldwide citation)

The present invention is directed toward a recombinant virus particle vaccine comprising a recombinant molecule packaged in an alphavirus coat. A preferred recombinant molecule of the present invention comprises a nucleic acid sequence that encodes a protective compound (e.g. a protective protein or ...


7
Paul Prem S, Halbur Patrick G, Meng Xiang Jin, Lum Melissa A, Lyoo Young S: Porcine respiratory and reproductive disease virus, vaccines and viral dna.. Solvay Animal Health, Univ Iowa Res Found, May 4, 1994: EP0595436-A2 (42 worldwide citation)

The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a ...


8
Cabezon Teresa, de Wilde Michel, Harford Nigel: Hepatitis b virus surface antigens and hybrid antigens containing them.. Smith Kline Rit, August 17, 1988: EP0278940-A2 (32 worldwide citation)

The invention relates to hepatitis B virus antigens and hybrid antigens containing them and to the cloning of genes which code for said antigens in yeast by use of recombinant DNA techniques. Said antigens are valuable for the preparation of vaccines, e.g. hepatitis B virus vaccines or malaria vacci ...


9
COLLER Beth Ann Griswold, PAI Vidya B, PARKS D Elliot, YELMENE Michele, BETT Andrew J, MARTYAK Timothy: VACCIN À SOUS-UNITÉ RECOMBINANTE CONTRE LE VIRUS DE LA DENGUE, RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE. MERCK SHARP & DOHME, COLLER Beth Ann Griswold, PAI Vidya B, PARKS D Elliot, YELMENE Michele, BETT Andrew J, MARTYAK Timothy, November 15, 2012: WO/2012/154202 (32 worldwide citation)

The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulat ...


10
Prem S Paul, Patrick G Halbur, Xiang Jin Meng, Young S Lyoo, Melissa Anne Lum: Isolated porcine respiratory and reproductive virus, vaccines and methods of protecting a pig against a disease caused by a porcine respiratory and reproductive virus. Iowa State University Research Foundation, Solvay Animal Health, Oblon Spivak McClelland Maier & Neustadt P C, August 29, 2000: US06110467 (26 worldwide citation)

The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a ...



Click the thumbnails below to visualize the patent trend.